Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering.
On the company’s first-quarter earnings call, Chief Executive Officer Claire Mazumdar said Bicara remains focused on advancing FICERA, which she described as a potentially “best and first-in-class” bifunctional EGFR-directed antibody combined with a TGF-beta ligand trap for the treatment of HPV-negative first-line head and neck cancer.
